Related Experiment Videos
Long-term visual field progression after Ex-PRESS implantation versus trabeculectomy in refractory glaucoma
Mitsuya Otsuka1, Yasuhito Nitta2, Ryota Akai2
1Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama City, 930-0194, Japan. otsuka@med.u-toyama.ac.jp.
International Ophthalmology
|August 7, 2026
Summary
Ex-PRESS filtration surgery and trabeculectomy showed similar long-term visual field progression in glaucoma patients. This suggests non-IOP factors may influence vision outcomes when intraocular pressure is controlled.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Surgical Outcomes
Background:
- Glaucoma management often involves surgical intervention to control intraocular pressure (IOP).
- Trabeculectomy is a traditional glaucoma surgery, while Ex-PRESS filtration surgery is a newer alternative.
- Long-term functional outcomes, specifically visual field progression, require further comparative analysis.
Purpose of the Study:
- To compare the long-term visual field progression between Ex-PRESS filtration surgery and trabeculectomy.
- To focus on functional visual outcomes rather than solely on intraocular pressure (IOP) control.
- To evaluate outcomes in patients with medically uncontrolled glaucoma.
Main Methods:
- Retrospective analysis of 109 eyes (Ex-PRESS: 51; trabeculectomy: 58) followed for ≥3 years.
- Exclusion of eyes requiring additional glaucoma surgery within 36 months.
- Quantification of visual field progression using the mean deviation (MD) slope (dB/year) via Humphrey or AP-7700 programs, analyzed with a linear mixed-effects model.
Main Results:
- Postoperative IOP was comparable between Ex-PRESS (11.8±2.6 mmHg) and trabeculectomy (11.4±3.0 mmHg) groups.
- Adjusted mean deviation (MD) slopes were -0.20 dB/year for Ex-PRESS and -0.15 dB/year for trabeculectomy (p=0.59).
- Subgroup analyses and correlation with blood pressure did not reveal significant differences in visual field progression.
Conclusions:
- No significant difference in long-term visual field progression was observed between Ex-PRESS implantation and trabeculectomy in eyes without reoperation within 36 months.
- When postoperative IOP is well-controlled, non-IOP vascular factors may contribute to residual visual field progression.
- This study adds to the limited evidence on long-term visual field outcomes following Ex-PRESS implantation.
Related Concept Videos
Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...